 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
The Current Status and Challenges for Antifungal Susceptibility Testing |
| Language |
J |
| AuthorList |
Hideyo Yamaguchi |
| Affiliation |
Teikyo University Institute of Medical Mycology |
| Publication |
J.J.C.M.: 14 (3), 129-145, 2004 |
| Received |
October 5, 2004 |
| Accepted |
|
| Abstract |
Although new antifungal drugs of both preexisting and new classes are steadily introduced, the incidence of deep-seated fungal infections caused by Candida spp., Aspergillus spp. and other pathogenic fungi including those species or strains low-susceptible or resistant to currently available antifungal drugs is still increasing. With these situations comes a growing need for clinically relevant susceptibility testing methodologies that can be used in choosing the best treatment strategy for a given patient. Actually, antifungal susceptibility testing has evolved rapidly during the last decades and has now become a relevant clinical tool, so that routine susceptibility testing with azoles and flucytosine is appropriate for Candida isolates and, to a lesser degree, C. neoformans isolates. However, this is not the case at present for amphotericin B or mold fungi. A more problematic issue is the lack of reference method for testing the susceptibility to candins, a recently introduced major class of antifungal drugs, that warrants further investigation and development. |
| Keywords |
NCCLS M27-A |
|
